Defence Therapeutics Inc.
DTC
Pozycja w akcjach
#29535
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Cena akcji
$0.25964327
Kapitalizacja rynkowa
$19.68M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-55.64%
Kraj
CA
Handel Defence Therapeutics Inc. (DTC)
Kategoria
Healthcare
Historia ceny akcji dla Defence Therapeutics Inc. (DTC)
Najwyższa cena zamknięcia: $0.27 dnia 2026-10-01
Najniższa cena zamknięcia: $2.50 dnia 2021-05-01
Najniższa cena zamknięcia: $2.50 dnia 2021-05-01
Historia cen akcji firmy Defence Therapeutics Inc. od 2021 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -27.55% |
| 2025 | 58.71% |
| 2024 | -79.59% |
| 2023 | -28.12% |
| 2022 | -37.44% |
| 2021 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $137.75 | -3.72% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
